Advanced search
Publication Cover
Blood and Lymphatic Cancer: Targets and Therapy Volume 12, 2022 - Issue
Submit an article Journal homepage
313
Views
5
CrossRef citations to date
0
Altmetric
Review

Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia

Kyaw HeinDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-1247-9632
ORCID Icon,
Nicholas ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
&
Musa YilmazDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
Pages 7-16 | Published online: 19 Mar 2022

Figures & data

Figure 1 Measurable Residual Disease Assessment Methods.

Note: Created with https://BioRender.com.
Abbreviations: IG/TCR, immunoglobulin and T-cell receptor; Pre-Rx, before treatment.
Figure 1 Measurable Residual Disease Assessment Methods.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.